title: [Autologous bone marrow transplantation for CML].
abstract: The first line therapy for CML is IFN-alpha and/or allogeneic hematopoietic stem cell transplantation(HSCT). The indication of autologous HSCT is limited for patients with no HLA-matched donor, and is recognized as an experimental therapy. Major problems of autologous HSCT for CML are contamination of Ph1-positive cells to graft and no GVL effects. To concur these problems, many attempts have been made such as the collection of peripheral blood stem cells after high dose chemotherapy, ex vivo purging using antisense, administration cyclosporin to induce GVL effect, and post-HSCT therapy by IFN-alpha +/- Interleukin-2. Autologous HSCT for CML is still to be a hopeful candidate for pursuing cure.
authors.affiliation: Department of Safety and Ethical Evaluation, Research Hospital, Institute of Medical Science, University of Tokyo.
authors.forename: F
authors.initials: F
authors.lastname: Nagamura
authors.forename: T
authors.initials: T
authors.lastname: Nagamura-Inoue
mesh_terms: D016465:Bone Marrow Purging; D016026:Bone Marrow Transplantation; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D014182:Transplantation, Autologous